Alliance Wealth Advisors LLC UT Has $670,000 Stock Position in Eli Lilly and Company (NYSE:LLY)

Alliance Wealth Advisors LLC UT grew its position in Eli Lilly and Company (NYSE:LLY) by 3.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 1,150 shares of the company’s stock after acquiring an additional 35 shares during the period. Alliance Wealth Advisors LLC UT’s holdings in Eli Lilly and Company were worth $670,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Simon Quick Advisors LLC grew its holdings in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $363,000. Hartline Investment Corp grew its holdings in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after buying an additional 248 shares during the period. Meritage Portfolio Management grew its holdings in shares of Eli Lilly and Company by 23.4% in the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after buying an additional 1,208 shares during the period. Finally, WASHINGTON TRUST Co lifted its position in Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after acquiring an additional 2,671 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.13% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LLY shares. Bank of America boosted their price objective on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $8.64 on Friday, reaching $733.51. The stock had a trading volume of 2,009,249 shares, compared to its average volume of 2,265,427. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm’s 50-day moving average is $761.79 and its two-hundred day moving average is $666.06. The firm has a market capitalization of $696.95 billion, a price-to-earnings ratio of 126.47, a P/E/G ratio of 1.58 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $380.77 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.09 EPS. On average, research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.